UPC vs. SBFM, IBIO, GRAY, ENVB, SHPH, HILS, TENX, ADXS, TRVN, and AIMD
Should you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Sunshine Biopharma (SBFM), iBio (IBIO), Graybug Vision (GRAY), Enveric Biosciences (ENVB), Shuttle Pharmaceuticals (SHPH), Hillstream BioPharma (HILS), Tenax Therapeutics (TENX), Ayala Pharmaceuticals (ADXS), Trevena (TRVN), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
Universe Pharmaceuticals (NYSE:UPC) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.
Universe Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Universe Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.70%. Universe Pharmaceuticals' return on equity of 0.00% beat Sunshine Biopharma's return on equity.
Sunshine Biopharma received 1 more outperform votes than Universe Pharmaceuticals when rated by MarketBeat users.
In the previous week, Sunshine Biopharma had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for Sunshine Biopharma and 1 mentions for Universe Pharmaceuticals. Sunshine Biopharma's average media sentiment score of 0.50 beat Universe Pharmaceuticals' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.
Sunshine Biopharma has lower revenue, but higher earnings than Universe Pharmaceuticals.
0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Sunshine Biopharma has a consensus price target of $260.00, indicating a potential upside of 24,659.55%. Given Sunshine Biopharma's higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Universe Pharmaceuticals.
Summary
Universe Pharmaceuticals and Sunshine Biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Universe Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Universe Pharmaceuticals Competitors List
Related Companies and Tools
